A discrete-choice experiment to assess patients’ preferences for osteoarthritis treatment: an ESCEO working group

Accepted/In Press date: 1 August 2020

Published date: October 2020

Additional Information: Funding Information: Professor Bruyère reports grants from Biophytis, IBSA, MEDA, Servier, SMB, Theramex, outside the submitted work. Professor Cooper reports personal fees from Alliance for Better Bone Health, Amgen, Eli Lilly, GSK, Medtronic, Merck, Novartis, Pfizer, Roche, Servier, Takeda and UCB. Professor Conaghan has received consulting fees or done speakers bureaus for AbbVie, EMD Serono, Flexion Therapeutics, Galapagos, Novartis, Pfizer, Samumed and Stryker. Professor Dennison has received consulting fees from UCB and Pfizer. Dr. Herrero-Beaumont reports grants from Novartis, grants from Sandoz, grants from Pfizer, grants from Amgen, grants from Mylan, grants from Servier, outside the submitted work; In addition, Dr. Herrero-Beaumont has a patent Patent for the use of 6-shogaol on osteoporosis treatment. Spanish patent issued, and a patent Patent on the use of osteostatin in osteoarthritis treatment issued. Professor Reginster reports grants and personal fees from IBSA-GENEVRIER, grants and personal fees from MYLAN, grants and personal fees from RADIUS HEALTH, personal fees from PIERRE FABRE, grants from CNIEL, personal fees from DAIRY RESEARCH COUNCIL, outside the submitted work. Professor Thomas reports personal fees from Abbvie, grants and personal fees from Amgen, personal fees from Arrow, personal fees from Biogen, personal fees from BMS, grants and personal fees from Chugai, personal fees from Expanscience, personal fees from Gilead, personal fees from Grunenthal, grants and personal fees from HAC-Pharma, personal fees from LCA, personal fees from Lilly, personal fees from Medac, grants and personal fees from MSD, grants and personal fees from Novartis, grants and personal fees from Pfizer, personal fees from Sanofi, personal fees from Theramex, personal fees from Thuasne, personal fees from TEVA, grants and personal fees from UCB, grants from Bone therapeutics, personal fees from Nordic, outside the submitted work. Professor Rizzoli reports personal fees from Amgen, CNiEL, Danone, Mylan, Nestle, Radius health, Sandoz, TEVA/Theramex, outside the submitted work. The other authors have no conflict of interest relevant to the content of this study. Funding Information: This work was supported by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases ( ESCEO ). Funding Information: We thank the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) for support. The authors are further grateful to the Chair for Biomarkers of Chronic Diseases in King Saud University , Riyadh, Saudi Arabia, for its support, and would like to thank all patients for their participation as well as all doctors and research assistants for helping us in recruiting patients. PGC is supported in part by the UK National Institute for Health Research (NIHR) through the Leeds Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. Publisher Copyright: © 2020 The Authors

Keywords: Discrete-choice experiment, Osteoarthritis, Outcomes, Patient preferences

Local EPrints ID: 443939

URI: http://eprints.soton.ac.uk/id/eprint/443939

DOI: doi:10.1016/j.semarthrit.2020.08.005

ISSN: 0049-0172

PURE UUID: 9098a797-4ad0-45f6-8a92-8b1b5f6484d2

ORCID for Elaine Dennison: orcid.org/0000-0002-3048-4961

ORCID for Cyrus Cooper: orcid.org/0000-0003-3510-0709

Date deposited: 17 Sep 2020 16:34

Last modified: 18 Mar 2024 02:46